"Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Descriptor ID |
D009369
|
| MeSH Number(s) |
C04
|
| Concept/Terms |
Neoplasms- Neoplasms
- Neoplasia
- Neoplasias
- Neoplasm
- Tumors
- Tumor
Cancer- Cancer
- Cancers
- Malignant Neoplasms
- Malignant Neoplasm
- Neoplasm, Malignant
- Neoplasms, Malignant
- Malignancy
- Malignancies
Benign Neoplasms- Benign Neoplasms
- Neoplasms, Benign
- Benign Neoplasm
- Neoplasm, Benign
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms".
This graph shows the total number of publications written about "Neoplasms" by people in this website by year, and whether "Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 7 | 1 | 8 |
| 2004 | 10 | 3 | 13 |
| 2005 | 7 | 2 | 9 |
| 2006 | 8 | 2 | 10 |
| 2007 | 12 | 2 | 14 |
| 2008 | 10 | 0 | 10 |
| 2009 | 11 | 3 | 14 |
| 2010 | 20 | 5 | 25 |
| 2011 | 14 | 4 | 18 |
| 2012 | 15 | 6 | 21 |
| 2013 | 19 | 4 | 23 |
| 2014 | 17 | 2 | 19 |
| 2015 | 24 | 1 | 25 |
| 2016 | 36 | 2 | 38 |
| 2017 | 33 | 2 | 35 |
| 2018 | 28 | 5 | 33 |
| 2019 | 36 | 8 | 44 |
| 2020 | 51 | 3 | 54 |
| 2021 | 52 | 4 | 56 |
| 2022 | 44 | 2 | 46 |
| 2023 | 29 | 0 | 29 |
| 2024 | 23 | 10 | 33 |
| 2025 | 55 | 0 | 55 |
| 2026 | 8 | 0 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasms" by people in Profiles.
-
Top advances of the year: Palliative and supportive care in oncology. Cancer. 2026 Apr 15; 132(8):e70392.
-
Planned time burden for patients participating in phase 2 cancer trials. Oncologist. 2026 Apr 10; 31(5).
-
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2. Clin Cancer Res. 2026 Apr 01; 32(7):1224-1233.
-
Treatment Decision-Making Roles and Preferences Among Adolescents and Young Adults With Cancer. Pediatr Blood Cancer. 2026 Jun; 73(6):e70235.
-
Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors. Cancer Chemother Pharmacol. 2026 Mar 14; 96(1).
-
Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E. JCO Precis Oncol. 2026 Feb; 10:e2500612.
-
Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism. Int J Mol Sci. 2026 Feb 12; 27(4).
-
Use of supportive care services and advance care planning among early phase oncology clinical trial participants. Support Care Cancer. 2026 Jan 21; 34(2):112.
-
The Unique Utility of Newborn Dried Blood Spots for Driving Discovery in Childhood Cancer Research. Clin Chem. 2025 Dec 30; 72(1):82-100.
-
MyPainPal, a Novel mHealth App to Improve Pain in Patients With Advanced Cancer: Single-Arm Pilot Study. JMIR Cancer. 2025 Dec 30; 11:e79942.